Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
96.88
+0.28 (0.29%)
At close: Nov 21, 2025, 4:00 PM EST
96.88
0.00 (0.00%)
After-hours: Nov 21, 2025, 7:55 PM EST
Boston Scientific Revenue
Boston Scientific had revenue of $5.07B in the quarter ending September 30, 2025, with 20.34% growth. This brings the company's revenue in the last twelve months to $19.35B, up 21.61% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$19.35B
Revenue Growth
+21.61%
P/S Ratio
7.40
Revenue / Employee
$365,075
Employees
53,000
Market Cap
143.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
| Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
| Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
| Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
| Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BSX News
- 3 days ago - Boston Scientific Corporation (BSX) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript - Seeking Alpha
- 15 days ago - Artisan Global Opportunities Fund Q3 2025 Portfolio Update - Seeking Alpha
- 18 days ago - Boston Scientific announces upcoming investor conference schedule - PRNewsWire
- 25 days ago - Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 4 weeks ago - Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy - Seeking Alpha
- 4 weeks ago - These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings - Benzinga
- 4 weeks ago - Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Boston Scientific lifts annual profit forecast on strong demand for heart devices - Reuters